Today's Highlights
Premium
Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today
Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders On October 9, 2019 Ionis Pharmaceuticals ( IONS ) announced it had been notified by its partner Bayer ( BAYN ) about the decision to adva...
P
Prohost Biotech
1 min read
3
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion